In Agilent Technologies, Inc. v. Sytnhego Corp., the US Court of Appeals for the Federal Circuit affirmed final written decisions by the Patent and Trademark Appeal Board (PTAB) finding that all challenged claims were unpatentable as anticipated orobvious and rejecting the patent owner’s argument that the key prior art reference was non-enabling under the US Supreme Court’s Amgen decision.
Source link
SCOTUS Amgen Decision Did Not Heighten Standard for Prior Art Enablement: Federal Circuit
